Clinical Trials Browser

INDUSTRY × Interventional × efineptakin alfa × Clear all

NCT04332653 2026-03-09

NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors

BreastGastrointestinalGynecologicThoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Thoracic Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT05075603 2025-10-23

Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy

Phase 1 Completed

17 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT03901573 2025-10-22

High-Risk Skin Cancers With Atezolizumab Plus NT-I7

Phase 1/2 Terminated

31 enrolled 12 charts

Dermatologic

Melanoma, Carcinoma, Merkel Cell

NCT04594811 2024-08-16

NT-I7 in Combination With Nivolumab in Advanced Gastric, Gastro-Esophageal Junction or Esophageal Adenocarcinoma

Phase 1 Terminated

10 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT06344715 2024-04-03

Phase 1 Study Evaluating Safety and Tolerability of SL-T10, GX-I7, and Pembrolizumab Triple Combination in mCRPC.

Phase 1 Recruiting

78 enrolled

Genitourinary

Metastatic Castration-resistant Prostate Cancer (mCRPC)

NCT03752723 2024-03-05

KEYNOTE-899

Phase 1/2 Completed

84 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04984811 2024-03-05

NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC

Phase 2 Active not recruiting

83 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT04065087 2022-03-17

Efficacy and Safety Study of GX-I7 Plus Adjuvant Temozolomide Combination in Patients With Newly Diagnosed Glioblastoma

Phase 1/2 Withdrawn

CNS

Newly Diagnosed Glioblastoma

NCT03733587 2020-05-14

GX-I7 With Cyclophosphamide in Patients With Metastatic or Recurrent Solid Tumors

Phase 1 Completed

24 enrolled

Other solid neoplasm

Solid Tumor

NCT03478995 2020-05-11

Study to Evaluate Safety and Tolerability of GX-I7 in Patients With Locally Advanced or Metastatic Solid Tumors

Phase 1 Completed

35 enrolled

Other solid neoplasm

Locally Advanced or Metastatic Solid Tumors